- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Treatment policies of Japanese institutions for borderline resectable pancreatic cancer
-
- SAHARA Yatsuka
- Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University
-
- NAGAKAWA Yuichi
- Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University
-
- HOSOKAWA Yuichi
- Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University
-
- MURAKAMI Yoshiaki
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University
-
- NAGAKAWA Takukazu
- Department of Gastroenterological Surgery, Kanazawa University
-
- TSUCHIDA Akihiko
- Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University
Bibliographic Information
- Other Title
-
- 3．Borderline resectable膵癌治療における各施設の治療方針
- ―日本膵切研究会のアンケート調査の結果より―
- -Results of an audit questionnaire by the Japanese Society of Pancreatic Surgery-
Search this article
Description
<p>Preoperative treatment has been implemented to improve the survival rate of borderline resectable (BR) pancreatic cancer, but specific recommendations have not been established for treatment policies. In order to grasp the current state of the treatment policy for BR pancreatic cancer in Japan, an audit questionnaire was administered to participating institutions of the Japanese Society of Pancreatic Surgery and responses were obtained from 74 institutions. Many institutions conducted preoperative treatment in both BR-A and BR-PV, but 23 institutions (33%) treated with BR-PV with upfront surgery. For preoperative treatment, 27 institutions (57%) used chemotherapy and 20 institutions (43%) used chemoradiotherapy for BR-PV. GEM+nabPTX was the most frequent chemotherapy regimen at 14 institutions, and S-1+radiation therapy or GEM+S-1+radiation therapy was utilized at 7 institutions. Preoperative treatment for BR-A pancreatic cancer was almost the same as for BR-PV. However, for BR-PV, approximately one-third of the institutions treated with upfront surgery.</p>
Journal
-
- Suizo
-
Suizo 33 (1), 27-36, 2018
Japan Pancreas Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679617712768
-
- NII Article ID
- 130006434151
-
- ISSN
- 18812805
- 09130071
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed